Literature DB >> 21185266

Cation-π and π-π stacking interactions allow selective inhibition of butyrylcholinesterase by modified quinine and cinchonidine alkaloids.

Sarfraz A Nawaz1, Muhammad Ayaz, Wolfgang Brandt, Ludger A Wessjohann, Bernhard Westermann.   

Abstract

Scaffold varied quaternized quinine and cinchonidine alkaloid derivatives were evaluated for their selective butyrylcholinesterase (BChE) inhibitory potential. K(i) values were between 0.4-260.5μM (non-competitive inhibition) while corresponding K(i)values to acetylcholinesterase (AChE) ranged from 7.0-400μM exhibiting a 250-fold selectivity for BChE. Docking arrangements (GOLD, PLANT) revealed that the extended aromatic moieties and the quaternized nitrogen of the inhibitors were responsible for specific π-π stacking and π-cation interactions with the choline binding site and the peripheral anionic site of BChE's active site.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21185266     DOI: 10.1016/j.bbrc.2010.12.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  4-Aminoquinoline-Based Adamantanes as Potential Anticholinesterase Agents in Symptomatic Treatment of Alzheimer's Disease.

Authors:  Katarina Komatović; Ana Matošević; Nataša Terzić-Jovanović; Suzana Žunec; Sandra Šegan; Mario Zlatović; Nikola Maraković; Anita Bosak; Dejan M Opsenica
Journal:  Pharmaceutics       Date:  2022-06-20       Impact factor: 6.525

2.  New Cinchona Oximes Evaluated as Reactivators of Acetylcholinesterase and Butyrylcholinesterase Inhibited by Organophosphorus Compounds.

Authors:  Maja Katalinić; Antonio Zandona; Alma Ramić; Tamara Zorbaz; Ines Primožič; Zrinka Kovarik
Journal:  Molecules       Date:  2017-07-22       Impact factor: 4.411

3.  Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.

Authors:  Weiam Hussein; Begüm Nurpelin Sağlık; Serkan Levent; Büşra Korkut; Sinem Ilgın; Yusuf Özkay; Zafer Asım Kaplancıklı
Journal:  Molecules       Date:  2018-08-14       Impact factor: 4.411

4.  Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold.

Authors:  Anita Bosak; Alma Ramić; Tamara Šmidlehner; Tomica Hrenar; Ines Primožič; Zrinka Kovarik
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.240

5.  Validation of the Antioxidant and Enzyme Inhibitory Potential of Selected Triterpenes Using In Vitro and In Silico Studies, and the Evaluation of Their ADMET Properties.

Authors:  Nilufar Z Mamadalieva; Fadia S Youssef; Hidayat Hussain; Gokhan Zengin; Adriano Mollica; Nawal M Al Musayeib; Mohamed L Ashour; Bernhard Westermann; Ludger A Wessjohann
Journal:  Molecules       Date:  2021-10-20       Impact factor: 4.411

6.  Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease.

Authors:  Prayasee Baruah; Abhinandan Das; Debojit Paul; Suman Chakrabarty; Kripamoy Aguan; Sivaprasad Mitra
Journal:  ACS Pharmacol Transl Sci       Date:  2021-01-06

7.  Anti-cholinesterase activity of the standardized extract of Syzygium aromaticum L.

Authors:  Manoj K Dalai; Santanu Bhadra; Sushil K Chaudhary; Arun Bandyopadhyay; Pulok K Mukherjee
Journal:  Pharmacogn Mag       Date:  2014-04       Impact factor: 1.085

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.